FATE Q3 2018 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+0.0% YoY

Gross Profit

-$13M-1229.1% margin

Operating Income

-$17M-1626.9% margin

Net Income

-$17M-1635.7% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

-0.1%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$220M

Total Liabilities

$46M

Stockholders' Equity

$174M

Cash & Equivalents

$183M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	+0.0%
Gross Profit	-$13M	-$8M	-67.0%
Operating Income	-$17M	-$10M	-61.4%
Net Income	-$17M	-$11M	-57.1%